Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) – Equities research analysts at William Blair cut their FY2024 earnings per share estimates for shares of Autolus Therapeutics in a report released on Monday, May 16th. William Blair analyst M. Phipps now anticipates that the company will earn ($1.43) per share for the year, down from their prior forecast of ($1.13). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Autolus Therapeutics’ FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($0.02) EPS.
Separately, Zacks Investment Research downgraded shares of Autolus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 21st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Autolus Therapeutics presently has a consensus rating of “Buy” and an average price target of $11.75.
Autolus Therapeutics (NASDAQ:AUTL – Get Rating) last announced its earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.10. Autolus Therapeutics had a negative net margin of 6,551.06% and a negative return on equity of 52.00%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.26 million. During the same period in the previous year, the business posted ($0.53) earnings per share.
A number of hedge funds have recently added to or reduced their stakes in AUTL. US Bancorp DE lifted its stake in Autolus Therapeutics by 182.3% during the third quarter. US Bancorp DE now owns 4,452 shares of the company’s stock valued at $30,000 after buying an additional 2,875 shares in the last quarter. Blair William & Co. IL bought a new stake in shares of Autolus Therapeutics in the 4th quarter worth about $58,000. Moloney Securities Asset Management LLC bought a new position in shares of Autolus Therapeutics in the first quarter worth about $83,000. Marshall Wace LLP acquired a new position in Autolus Therapeutics in the fourth quarter valued at approximately $85,000. Finally, Virtu Financial LLC acquired a new position in shares of Autolus Therapeutics in the 4th quarter valued at $88,000. Hedge funds and other institutional investors own 61.45% of the company’s stock.
About Autolus Therapeutics (Get Rating)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
- Get a free copy of the StockNews.com research report on Autolus Therapeutics (AUTL)
- The Weber, Inc Growth Story Goes Up In Smoke
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.